3 data and information 3 - update, page-88

re: pbt to take off in the states I hope it will.

People here are not able to grasp the importance of the findings.

And if Aussies don't want the shares, right, let the US have them.

That is the only way of raising prices.

Some more about the new drug PBT-2-see post 202504:
Extract:

Prana announced in August 2003 that it intended to take the best volume in its MPAC molecule library, a compound called PBT-2, into a formal clinical trial setting.

By eight different accounts studies both in vitro and in vivo have shown PBT-2 to be better than PBT-1. Probably the most important measures are ‘brain amyloid solubility’, which shows PBT-2 to be 2.5 times better at reducing amyloid plaques than PBT-1, and ‘inhibition of peroxide’, where PBT-2 is 1.6 times better at holding back H202 production than its predecessor compound.

These two measures indicate that PBT-2 works against ‘mechanistic targets’, that is, targets at work in what Prana believes is the underlying mechanism of action in Alzheimer’s Disease.

In terms of its ability as a drug to treat a central nervous system disorder, PBT-2 also scores more highly than PBT-1. The new drug is over ten times more soluble than PBT-1, which makes it a much easier drug to work with. PBT-2 has four times he ‘neuroprotective’ ability of PBT-1, meaning that the amyloid beta killed markedly fewer neurons when PBT-2 was used.

The ability of PBT-2 to get through the blood-brain barrier is much higher than PBT-1.

And finally, in transgenic mice that had been engineered
to suffer Alzheimer’s there was a 29% reduction in insoluble amyloid beta still in the brain and a 37% fall in soluble amyloid beta in the brain as a result of PBT-2.

By contrast PBT-1 could cut insoluble amyloid levels by nearly half but make no dent in soluble amyloid still in the brain.

In short, PBT-2 is a more powerful drug.

It probably won’t be until October 2004 that the formal clinical trial of PBT-2 begins. Toxicology studies are
currently being undertaken and the drug will have to be produced ahead of the start of the trial".